相关实验视频

Updated: Jun 11, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

复发性多发性硬化症中的大脑体积损失:可用的疾病修饰疗法的间接治疗比较

Robert Zivadinov^1,2, Alexander J Keenan³, Hoa H Le⁴

¹Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA.

|October 8, 2024

概括

疾病修饰治疗 (DMT) 在复发性多发性硬化症 (RMS) 中显著减缓大脑体积损失 (BVL). 与安慰剂相比,fingolimod,ozanimod,teriflunomide,alemtuzumab和ponesimod显示出BVL的显着减少.与安慰剂相比,fingolimod,ozanimod,teriflunomide,alemtuzumab和ponesimod显示了与安慰剂相比BVL的显著减少.

科学领域:

神经科学是一个神经科学.
临床试验临床试验
药理学药理学是指药理学的学科.

背景情况:

大脑体积损失 (BVL) 是复发性多发性硬化症 (RMS) 中残疾进展的关键指标.
疾病修饰疗法 (DMT) 越来越多地评估其减缓BVL的能力,使其成为临床试验中的重要终点.

研究的目的:

系统地审查和比较各种DMT在减少RMS患者BVL的疗效.
使用间接治疗比较 (ITC) 来估计不同DMT对BVL的相对有效性.

主要方法:

对随机对照试验 (RCT) 进行了系统的文献审查,调查RMS的DMT.
基于模型的元分析 (MBMA) 和网络元分析 (NMA) 用于间接的治疗比较,以时间点和剂量进行调整.

主要成果:

几种DMT,包括fingolimod,ozanimod,teriflunomide,alemtuzumab和ponesimod,在两年内显示出与安慰剂相比,BVL显著减少.
干扰素和纳塔利祖马布在BVL减少方面显示出不太有利的结果.
总体而言,NMA的结果证实了MBMA的调查结果.

结论:

在RMS的不同DMT之间,BVL减少存在显著差异.
对BVL的进一步研究对于了解DMT机制和补充传统的残疾措施至关重要.
局限性包括伪缩的潜在混以及缺乏长期BVL数据.

关键词:

大脑体积损失大脑体积损失改变疾病的治疗方法.磁共振成像技术磁共振成像技术基于模型的元分析.多发性硬化症是多发性硬化症.网络元分析网络元分析系统的文献审查系统的文献审查

更多相关视频

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...